- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01331681
Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID-DME)
November 5, 2023 updated by: Bayer
A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
406
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Parramatta, Australia, 2150
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2000
-
Westmead, New South Wales, Australia, 2145
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
-
-
-
-
-
Linz, Austria, 4021
-
Wien, Austria, 1090
-
-
Oberösterreich
-
Linz, Oberösterreich, Austria, 4020
-
-
-
-
-
Hradec Kralove, Czechia, 500 05
- Faculty Hospital Hradec Kralove
-
Olomouc, Czechia, 779 00
-
Ostrava, Czechia, 708 52
-
Praha 10, Czechia, 100 34
-
-
-
-
-
Glostrup, Denmark, 2600
-
Århus C, Denmark, 8000
-
-
-
-
-
Bordeaux, France, 33076
-
Creteil Cedex, France, 94010
-
Lyon, France, 69003
-
Nantes Cedex, France, 44093
-
Paris, France, 75010
- Hopital Lariboisiere
-
Paris, France, 75015
-
-
-
-
-
Berlin, Germany, 12203
-
-
Baden-Württemberg
-
Freiburg, Baden-Württemberg, Germany, 79106
-
Heidelberg, Baden-Württemberg, Germany, 69120
-
Tübingen, Baden-Württemberg, Germany, 72076
-
-
Bayern
-
München, Bayern, Germany, 81675
-
-
Hessen
-
Darmstadt, Hessen, Germany, 64297
-
-
Niedersachsen
-
Göttingen, Niedersachsen, Germany, 37075
-
-
Nordrhein-Westfalen
-
Aachen, Nordrhein-Westfalen, Germany, 52074
-
Bonn, Nordrhein-Westfalen, Germany, 53105
-
Köln, Nordrhein-Westfalen, Germany, 50924
-
-
Rheinland-Pfalz
-
Ludwigshafen, Rheinland-Pfalz, Germany, 67063
- Klinikum der Stadt Ludwigshafen am Rhein gGmbH
-
Mainz, Rheinland-Pfalz, Germany, 55131
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
-
-
-
-
-
Budapest, Hungary, 1083
-
Budapest, Hungary, 1106
-
Budapest, Hungary, 1133
-
Debrecen, Hungary, 4032
-
Veszprem, Hungary, 8200
-
Zalaegerszeg, Hungary, H-8900
-
-
-
-
-
Milano, Italy, 20122
- IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico
-
-
Lazio
-
Roma, Lazio, Italy, 00198
-
Roma, Lazio, Italy, 00133
-
-
Lombardia
-
Milano, Lombardia, Italy, 20157
-
-
Marche
-
Ancona, Marche, Italy, 60126
-
-
Veneto
-
Padova, Veneto, Italy, 35128
-
-
-
-
-
Akita, Japan, 010-8543
-
Chiba, Japan, 260-8677
-
Fukuoka, Japan, 812-8582
-
Nagasaki, Japan, 852-8501
-
Osaka, Japan, 545-8586
-
Wakayama, Japan, 641-8510
-
-
Aichi
-
Nagoya, Aichi, Japan, 466-8560
-
Nagoya, Aichi, Japan, 467-8602
-
-
Hokkaido
-
Asahikwa, Hokkaido, Japan, 078-8510
-
Sapporo, Hokkaido, Japan, 060-8648
-
-
Kanagawa
-
Kawasaki, Kanagawa, Japan, 216-8511
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
-
-
Nagano
-
Matsumoto, Nagano, Japan, 390-8621
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
-
-
Tokyo
-
Chiyoda-ku, Tokyo, Japan, 101-8309
-
Itabashi-ku, Tokyo, Japan, 173-8606
-
Mitaka, Tokyo, Japan, 181-8611
-
Shinjuku-ku, Tokyo, Japan, 162-8666
-
-
-
-
-
Bytom, Poland, 41-902
-
Wroclaw, Poland, 50-556
-
Wroclaw, Poland, 51-124
-
-
-
-
-
Alicante, Spain, 03016
-
Barcelona, Spain, 8036
-
Pamplona, Spain, 31008
-
Valencia, Spain, 46015
-
-
A Coruña
-
Santiago de Compostela, A Coruña, Spain, 15706
-
-
Asturias
-
Oviedo, Asturias, Spain, 33012
-
-
Barcelona
-
San Cugat Del Vallès, Barcelona, Spain, 08190
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults ≥ 18 years with type 1 or 2 diabetes mellitus
- Subjects with DME secondary to diabetes mellitus involving the center of the macula in the study eye
- Decrease in vision determined to be primarily the result of DME in the study eye
- BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye
Exclusion Criteria:
- Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1
- More than 2 previous macular laser treatments in the study eye
- Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of Day 1
- Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1
- Active proliferative diabetic retinopathy (PDR) in the study eye, with the exception of inactive, regressed PDR
- Uncontrolled diabetes mellitus, as defined by HbA1c > 12%
- Only 1 functional eye even if that eye is otherwise eligible for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravitreal Aflibercept Injection 2Q4
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
|
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
|
Experimental: Intravitreal Aflibercept Injection 2Q8
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
|
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
|
Active Comparator: Macular Laser Photocoagulation (Control)
Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
|
Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)
Time Frame: Baseline up to Week 52
|
Visual function of the study eye was assessed using the ETDRS protocol.
A higher score represents better functioning.
|
Baseline up to Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Time Frame: Baseline up to Week 52
|
Visual function of the study eye was assessed using the ETDRS protocol.
A higher score represents better functioning.
|
Baseline up to Week 52
|
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Time Frame: Baseline up to Week 52
|
Visual function of the study eye was assessed using the ETDRS protocol.
A higher score represents better functioning.
|
Baseline up to Week 52
|
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF
Time Frame: Baseline up to Week 52
|
Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
|
Baseline up to Week 52
|
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
Time Frame: Baseline up to Week 52
|
Baseline up to Week 52
|
|
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF
Time Frame: Baseline up to Week 52
|
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome.
The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100.
Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
|
Baseline up to Week 52
|
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF
Time Frame: Baseline up to Week 52
|
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome.
The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100.
Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.
|
Baseline up to Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Bayer Study Director, Bayer
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Midena E, Gillies M, Katz TA, Metzig C, Lu C, Ogura Y. Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies. J Ophthalmol. 2018 Mar 29;2018:3640135. doi: 10.1155/2018/3640135. eCollection 2018.
- Staurenghi G, Feltgen N, Arnold JJ, Katz TA, Metzig C, Lu C, Holz FG; VIVID-DME and VISTA-DME study investigators. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol. 2018 Jul;102(7):954-958. doi: 10.1136/bjophthalmol-2017-310664. Epub 2017 Oct 19.
- Wykoff CC, Marcus DM, Midena E, Korobelnik JF, Saroj N, Gibson A, Vitti R, Berliner AJ, Williams Liu Z, Zeitz O, Metzig C, Schmelter T, Heier JS. Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials. JAMA Ophthalmol. 2017 Feb 1;135(2):107-114. doi: 10.1001/jamaophthalmol.2016.4912.
- Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data. Int J Retina Vitreous. 2016 Jul 11;2:16. doi: 10.1186/s40942-016-0041-z. eCollection 2016.
- Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8.
- Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015 Oct;122(10):2044-52. doi: 10.1016/j.ophtha.2015.06.017. Epub 2015 Jul 18.
- Keating GM. Aflibercept: A Review of Its Use in Diabetic Macular Oedema. Drugs. 2015 Jul;75(10):1153-60. doi: 10.1007/s40265-015-0421-y.
- Nanegrungsunk O, Gu SZ, Bressler SB, Du W, Amer F, Moini H, Bressler NM. Correlation of Change in Macular Thickness With Change in Visual Acuity in Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials. J Vitreoretin Dis. 2022 Jul 27;6(4):284-289. doi: 10.1177/24741264221099429. eCollection 2022 Jul-Aug.
- Valentim CCS, Singh RP, Du W, Moini H, Talcott KE. Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID. Ophthalmol Retina. 2023 Jan;7(1):24-32. doi: 10.1016/j.oret.2022.07.004. Epub 2022 Jul 14.
- Dhoot DS, Moini H, Reed K, Du W, Vitti R, Berliner AJ, Singh RP. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials. Eye (Lond). 2023 Jul;37(10):2020-2025. doi: 10.1038/s41433-022-02058-7. Epub 2022 Apr 19.
- Do DV, Gordon C, Suner IJ, Reed K, Moini H, Gibson A, Du W, Shah CP. Proliferative Diabetic Retinopathy Events in Patients With Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials. J Vitreoretin Dis. 2022 Jun 4;6(4):295-301. doi: 10.1177/24741264221093914. eCollection 2022 Jul-Aug.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 9, 2011
Primary Completion (Actual)
June 3, 2013
Study Completion (Actual)
March 30, 2015
Study Registration Dates
First Submitted
April 7, 2011
First Submitted That Met QC Criteria
April 7, 2011
First Posted (Estimated)
April 8, 2011
Study Record Updates
Last Update Posted (Actual)
November 27, 2023
Last Update Submitted That Met QC Criteria
November 5, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 91745
- 2010-022364-12 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on VEGF Trap-Eye (BAY86-5321)
-
Regeneron PharmaceuticalsBayerCompleted
-
Regeneron PharmaceuticalsBayerCompletedMacular DegenerationUnited States, Canada
-
BayerRegeneron PharmaceuticalsActive, not recruitingNeovascular Age-Related Macular DegenerationSpain, Korea, Republic of, Czechia, Japan, Singapore, United States, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Portugal, Bulgaria, Latvia, Canada, Hungary, Arge... and more
-
BayerCompleted
-
BayerRegeneron PharmaceuticalsRecruitingMacular Edema Secondary to Retinal Vein OcclusionKorea, Republic of, Japan, China, Lithuania, United States, Italy, Spain, Hungary, Israel, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Germany, Latvia, Mal... and more
-
BayerCompletedMacular Degeneration | Choroidal NeovascularizationGreece
-
BayerCompletedMacular EdemaSpain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, Germany, Hungary, Italy, France, Lithuania, Czechia
-
BayerRegeneron PharmaceuticalsCompletedChoroidal NeovascularizationJapan
-
BayerRegeneron PharmaceuticalsCompleted
-
BayerRegeneron PharmaceuticalsCompletedMacular DegenerationJapan